Infectious Disease Frontier

Bloodstream infection (BSI) is a severe systemic infection, especially with multidrug-resistant bacteria such as carbapenem-resistant Gram-negative organisms (CRO), posing a significant threat to patient safety. Clinical management of BSI faces numerous challenges, with early diagnosis and precise treatment being crucial for improving patient outcomes. At the recent 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2024), V. Anton-Vazquez and colleagues from St. George's University Hospital NHS Foundation Trust in the UK presented a study titled "Clinical Outcomes and Factors Associated with Optimal Antibiotic Therapy in Gram-Negative BSI: A Post Hoc Analysis of a Comparative Study between Rapid and Conventional Antimicrobial Susceptibility Testing." Infection Medicine has invited Professor Chongjie Pang  from Tianjin Medical University General Hospital to provide an in-depth commentary on this study, asking him to further elucidate its clinical significance and value based on his clinical experience.

Cefiderocol is a novel siderophore cephalosporin antibiotic with excellent stability against nearly all β-lactamases, including metalloenzymes. It has demonstrated good clinical efficacy against infections caused by carbapenem-resistant Gram-negative bacteria (CRO), garnering significant attention from experts in the field of infectious diseases. At the 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2024), a multicenter, open-label randomized study (abstract number: O0810) compared the efficacy of cefiderocol with standard therapy in treating healthcare-associated and hospital-acquired Gram-negative bloodstream infections (BSI). "Infectious Disease Frontier" invited Professor YongHong Xiao from The First Affiliated Hospital of Zhejiang University School of Medicine to provide professional commentary on this study, analyzing the potential and prospects of cefiderocol in treating Gram-negative BSI.

Infection remains a major challenge for recipients of solid organ transplants (SOT), leading to serious risks of mortality and transplant failure. Previous research has primarily focused on the characteristics and prevention of infections within the first year post-surgery, with limited data on long-term infections beyond one year post-surgery. At the recent 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2024 Annual Meeting, a large-scale follow-up study from Switzerland reported that SOT recipients still face a high incidence of infections and disease burden beyond one year post-surgery.

From April 27th to 30th, 2024, the 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2024) took place in Barcelona, Spain, known as the "Pearl of the Iberian Peninsula." ESCMID Global, formerly known as ECCMID, stands as one of the most influential international conferences in the field of infectious diseases. Often, clinical trials of antibiotics exclude special populations such as obese or underweight individuals, resulting in limited evidence for their treatment strategies. At this conference, several studies and advancements regarding antibiotic management and prescription, including interventions, monitoring, influences, decision support/predictive tools, and behavioral aspects, were reported. Below is a summary of the insights shared by Professor Wenxiang Huang from the Department of Geriatrics at The First Affiliated Hospital of Chongqing Medical University.

Editor's Note: Traditional microbiology laboratory methods such as Gram staining and antimicrobial susceptibility testing still rely on manual interpretation of results and report generation. The introduction of artificial intelligence (AI)…

In low- and middle-income countries, the health of newborns faces numerous challenges, with neonatal sepsis being a particularly grave concern. At the 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2024), a study (abstract number: O0158) focused on the threat posed by Coagulase-Negative Staphylococci (CoNS) to newborn health. These bacteria, increasingly reported in low- and middle-income countries, exhibit insensitivity to multiple commonly used antibiotics, complicating treatment. Professor Qing Cao from the Shanghai Children's Medical Center, affiliated with Shanghai Jiao Tong University School of Medicine, provides a detailed commentary on this study, sharing her professional insights and recommendations.

Anthrax is a zoonotic infectious disease caused by Bacillus anthracis infection, which still occurs sporadically in some areas of China. Anthrax can manifest in various clinical forms, with pulmonary anthrax having a mortality rate of over 80% and requiring management as a Class A infectious disease. In order to further standardize the clinical diagnosis and treatment of anthrax, the National Health Commission issued the "Anthrax Diagnosis and Treatment Plan (2023 Edition)." At the recent Fourth National Congress of the Chinese Society of Infectious Diseases (BISC 2024), Professor Junyan Qu, the secretary-general of the conference and from the Infectious Diseases Center of West China Hospital, Sichuan University, interpreted the diagnosis and treatment plan based on case studies. The summary is presented below.

With the escalating issue of antimicrobial resistance globally, newly emerged resistant strains pose a serious threat to public health. At the 34th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2024), a study by Professor Ning Shen 's team from Peking University Third Hospital (Abstract No.: E0451) focused on the resistance issues of cefiderocol, a drug not yet marketed in China. The study discovered that cefiderocol can induce resistance in vitro and amplify the blaSHV-12 gene. Long-read sequencing technology demonstrated its potential in the rapid and accurate detection of resistance gene amplification, offering a new tool for future resistance research.

Non-tuberculous mycobacteria (NTM) refers to all mycobacteria other than Mycobacterium tuberculosis and Mycobacterium leprae. NTM most commonly affect the lungs, causing NTM pulmonary disease (NTM-PD), which can even lead to disseminated disease in immunocompromised individuals. In recent years, with changes in the environment, updates in detection technology, and increased awareness among physicians, the incidence of NTM-PD has been steadily increasing, with Mycobacterium avium complex (MAC) pulmonary disease being the most common worldwide. At the recent Fourth National Conference of the Chinese Medical Association on Bacterial and Fungal Infections (BISC 2024), Professor Hongfei Duan from the Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, delivered a fascinating presentation titled "Advances in Diagnosis and Treatment of Mycobacterium avium Complex Pulmonary Disease," elucidating and analyzing the current status, challenges, and progress in the diagnosis and treatment of MAC pulmonary disease.

Patients with hematological disorders are often immunocompromised due to their primary disease or treatment, making them susceptible to infections. These infections often present atypically and can be caused by a wide variety of pathogens. Traditional diagnostic methods have low positivity rates and are time-consuming. Pathogen diagnosis is crucial for optimizing anti-infection treatment and improving patient outcomes. Metagenomic Next-Generation Sequencing (mNGS) is a high-throughput, broad-coverage diagnostic technique that has been widely applied in clinical infection settings. In diagnosing infections in hematological patients, mNGS offers high positivity rates, minimal interference from antimicrobial drugs, and broad pathogen coverage. To standardize the application of mNGS in hematological patients and optimize report interpretation, the Infectious Diseases Group of the Chinese Society of Hematology has invited experts in the field to develop a consensus.